InsiderTrades

Form 4 for LXEO Lexeo Therapeutics, Inc.

Accepted 2025-10-17 00:00:00 ET · period of report 2025-10-15 · accession 0001995218-25-000005 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
2025-10-17 2025-10-15 LXEO Townsend Richard Nolan CEO, Dir A - Grant $0.00 +33.0K 255.3K +15% $0
M 2025-10-17 2025-10-17 LXEO Townsend Richard Nolan CEO, Dir S - Sale $8.95 -13.1K 242.1K -5% -$117.5K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-10-15 A A 33,000 $0.00 255,251 D — —
2 Common Common Stock 2025-10-17 S D 12,985 $8.94 242,266 D — — (F2) This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3 Common Common Stock 2025-10-17 S D 148 $9.56 242,118 D — — (F3) This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F4) Includes 131,092 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.